10-Q: Medpace Reports Strong Q3 2025 Growth, Boosts Backlog

Medpace Holdings, Inc. announced robust financial results for the third quarter and nine months ended September 30, 2025, driven by significant revenue and net new business award increases.

Summary

• Revenue increased by 23.7% to $659.9 million for Q3 2025 and by 15.9% to $1,821.8 million for the nine months ended September 30, 2025, compared to the prior year periods.
• Net income grew by 15.2% to $111.1 million for Q3 2025 and by 10.0% to $316.0 million for the nine months ended September 30, 2025.
• Diluted EPS rose by 28.2% to $3.86 for Q3 2025 and by 18.8% to $10.64 for the nine months ended September 30, 2025.
• Net new business awards for Q3 2025 were $789.6 million, a substantial increase from $533.7 million in Q3 2024.
• Year-to-date net new business awards reached $1,910.2 million, up from $1,700.3 million in the prior year.
• Backlog increased by 2.5% to $3,000.6 million as of September 30, 2025, compared to $2,927.4 million a year prior.
• Cash and cash equivalents decreased to $285.4 million as of September 30, 2025, from $669.4 million at December 31, 2024, primarily due to $917.4 million in common stock repurchases during the nine months.
• Operating cash flows for the nine months ended September 30, 2025, were $520.6 million, up from $418.1 million in the prior year.

Sentiment

Score: 8

Explanation: The company reported strong financial performance with significant increases in revenue, net income, and diluted EPS. Net new business awards and backlog also showed robust growth, indicating healthy demand and future revenue potential. While cash decreased due to substantial share repurchases, this reflects a strategic decision to return capital to shareholders and confidence in the company's valuation.

Positives

• Strong revenue growth of 23.7% for the quarter and 15.9% year-to-date, driven by Metabolic, Oncology, and Central Nervous System therapeutic areas.
• Significant increase in net income and diluted EPS for both the quarter and nine-month periods.
• Substantial growth in net new business awards, indicating strong demand for services.
• Backlog increased to over $3 billion, with a significant portion ($1,830.0 million to $1,850.0 million) expected to convert to revenue in the next 12 months.
• Robust net cash provided by operating activities, increasing to $520.6 million year-to-date.
• The company executed significant share repurchases totaling $917.4 million year-to-date, demonstrating confidence and returning capital to shareholders.

Negatives

• Cash and cash equivalents decreased significantly by $384.1 million year-to-date, primarily due to substantial share repurchases.
• Interest income, net, decreased by $6.0 million for the quarter and $8.1 million year-to-date, mainly due to decreased interest income on cash and cash equivalents.
• The effective income tax rate increased to 22.2% for the quarter and 18.0% year-to-date, partly due to a decrease in estimated tax benefits related to Foreign Derived Intangible Income (FDII).
• Total assets and total shareholders' equity decreased, largely influenced by the share repurchase program.

Risks

• The company refers to the 'Risk Factors' section in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and states there have been no significant changes from those previously disclosed.
• Forward-looking statements are subject to inherent uncertainties, risks, changes in circumstances, and other factors that are difficult to predict, including regional, national, or global political, economic, business, competitive, market, and regulatory conditions, government shutdowns, inflation, interest rates, and other pricing pressures.
• Contract cancellation provisions allow customers to terminate contracts with typically 30 days' notice, which can impact future revenue.
• Backlog and net new business award metrics may not be reliable indicators of future revenue due to factors like changes in project scope, cancellations, and service duration/timing.

Future Outlook

Medpace expects to convert approximately $1,830.0 million to $1,850.0 million of its current backlog into net revenue over the next twelve months. The company plans to continue expanding its operations through organic growth and potentially highly selective bolt-on acquisitions and investments. Foreign earnings are deemed indefinitely reinvested, and the company does not anticipate needing to repatriate them for liquidity purposes.

Management Comments

• We are one of the world's leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries.
• Our mission is to accelerate the global development of safe and effective medical therapeutics.
• We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our therapeutic expertise.
• We believe this combination results in timely and cost-effective delivery of clinical development services for our customers.
• We believe that we are a partner of choice for smalland mid-sized biopharmaceutical companies based on our ability to consistently utilize our full-service, disciplined operating model to deliver timely and high-quality results for our customers.
• We expect to continue expanding our operations through organic growth and potentially highly selective bolt-on acquisitions and investments.

Industry Context

Medpace operates as a leading global Clinical Research Organization (CRO), providing full-service clinical development services to the biotechnology, pharmaceutical, and medical device industries. The strong revenue growth, particularly in Metabolic, Oncology, and Central Nervous System therapeutic areas, indicates robust demand within the broader life sciences sector for outsourced clinical trial expertise. The increase in net new business awards and backlog suggests a healthy market for CRO services, reflecting ongoing R&D investment by biopharmaceutical companies. Medpace's focus on a scientifically-driven, full-service model positions it well to capture market share, especially among smalland mid-sized biopharmaceutical clients.

Corporate Governance

Legal Proceedings

• Involved in legal proceedings from time to time in the ordinary course of business, including employment claims and claims related to other business transactions.
• Believes adequate reserves have been recorded and losses already recognized are immaterial as of September 30, 2025 and December 31, 2024.
• Believes potential losses exceeding recognized amounts related to these actions were immaterial as of September 30, 2025.

Related Party Transactions

• Employee loans or advances totaled $0.4 million at September 30, 2025.
• Services provided to LIB Therapeutics LLC (where executives are board members) generated revenue of $1.8 million for Q3 2025 and $5.7 million for YTD 2025.
• Services provided to CinRX Pharma (where executives are board members and/or have equity investments) generated revenue of $10.4 million for Q3 2025 and $37.2 million for YTD 2025.
• Expenses incurred at The Summit Hotel (owned by the CEO) for travel lodging and meetings were $0.1 million for Q3 2025 and $0.2 million for YTD 2025.
• Operating leases for office space in Cincinnati, Ohio, from entities wholly owned by the CEO and/or his immediate family, resulted in significant operating lease costs and right-of-use assets. For Q3 2025, costs were $0.7 million, $1.5 million, $0.6 million, and less than $0.1 million for various leases.
• Travel services provided by CEO-controlled private aviation charter companies incurred expenses of $0.5 million for Q3 2025 and $1.4 million for YTD 2025, recorded in Selling, general and administrative expenses.

Stakeholder Impact

• Shareholders benefited from significant share repurchases ($917.4 million YTD 2025) and increased diluted EPS, indicating value return and improved profitability per share.
• Employees saw higher personnel costs to support growth and stock-based compensation expense, reflecting ongoing investment in human capital.
• Customers experienced continued demand for Medpace's clinical development services, as evidenced by strong revenue growth and increased backlog, suggesting successful customer relationships and project execution.
• Creditors face no immediate debt risk as the company had no indebtedness under its Credit Facility as of September 30, 2025.

Next Steps

• Adopt ASU 2023-09, 'Income Taxes (Topic 740): Improvements to Income Tax Disclosures,' in the fourth quarter of 2025.
• Evaluate the effect of ASU 2024-03, 'Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures,' and ASU 2025-06, 'Intangibles-Goodwill and Other-Internal-Use Software,' on consolidated financial statements and disclosures.
• Continue organic growth and pursue selective bolt-on acquisitions and investments.
• Manage the conversion of $1,830.0 million to $1,850.0 million of backlog to net revenue over the next twelve months.

Key Dates

Recommendation

Medpace demonstrated exceptional financial performance with robust revenue growth, significant increases in net income and diluted EPS, and a substantial rise in net new business awards and backlog. The company's strategic share repurchase program, totaling over $900 million year-to-date, signals strong management confidence and a commitment to returning value to shareholders. Despite a decrease in cash due to these repurchases, the underlying operational strength, growing pipeline, and strong cash flow from operations position Medpace for continued success in the high-demand CRO market. The company's focus on key therapeutic areas and its global platform further enhance its competitive advantage.

Keywords

Clinical Research Organization, CRO, Biotechnology, Pharmaceutical, Medical Device, Clinical Trials, Drug Development, Oncology, Metabolic Disease, Central Nervous System, Financial Results, SEC Filing, 10-Q, Share Repurchase, Backlog, Revenue Growth, EPS